Title:
MUTATED ANTI-CD22 ANTIBODIES WITH INCREASED AFFINITY TO CD22-EXPRESSING LEUKEMIA CELLS
Document Type and Number:
WIPO Patent Application WO2003027135
Kind Code:
A3
Abstract:
Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.
Inventors:
PASTAN IRA H (US)
SALVATORE GIULIANA (IT)
BEERS RICHARD (US)
KREITMAN ROBERT J (US)
SALVATORE GIULIANA (IT)
BEERS RICHARD (US)
KREITMAN ROBERT J (US)
Application Number:
PCT/US2002/030316
Publication Date:
March 11, 2004
Filing Date:
September 25, 2002
Export Citation:
Assignee:
US GOV HEALTH & HUMAN SERV (US)
PASTAN IRA H (US)
SALVATORE GIULIANA (IT)
BEERS RICHARD (US)
KREITMAN ROBERT J (US)
PASTAN IRA H (US)
SALVATORE GIULIANA (IT)
BEERS RICHARD (US)
KREITMAN ROBERT J (US)
International Classes:
A61K47/48; C07K16/28; (IPC1-7): C07H21/04; A61K39/395; C07K16/00; C12N15/63; G01N33/53
Other References:
SALVATORE ET AL.: "Improved cytotoxic activity cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display", CLINICAL CANCER RESEARCH, vol. 8, April 2002 (2002-04-01), pages 995 - 1002, XP002971541
Download PDF:
Previous Patent: COHALOGENATIONS OF SELECTED DOUBLE BONDED COMPOUNDS USING N-HALO-SUCCINIMIDE.
Next Patent: PROTEIN PRODUCTION
Next Patent: PROTEIN PRODUCTION